Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPY4R | P50391 | 12/20 | 0.44 |
| ▸ | NPY1R | P25929 | 8/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523268 | 0.94 | SIRT5 (0.53) | SIRT5TDP1RAB9ANPY4RNPY1R | |
| SCHEMBL29417414 | 0.94 | SIRT5 (0.53) | SIRT5TDP1RAB9ANPY4RNPY1R | |
| SCHEMBL29577662 | 0.94 | SIRT5 (0.53) | SIRT5TDP1RAB9ANPY4RNPY1R | |
| SCHEMBL6856707 | 0.94 | SIRT5 (0.49) | SIRT5TDP1RAB9ANPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL29692733 | 0.94 | SIRT5 (0.52) | SIRT5TDP1RAB9ANPY4RNPY1R | |
| SCHEMBL31045936 | 0.91 | SIRT5 (0.52) | SIRT5TDP1NPY4RNPY1R | |
| SCHEMBL4727432 | 0.90 | SIRT2 (0.49) | SIRT5TDP1RAB9A | |
| SCHEMBL4076285 | 0.90 | SIRT2 (0.49) | SIRT5TDP1RAB9A | |
| SCHEMBL29357392 | 0.90 | SIRT2 (0.49) | SIRT5TDP1RAB9A | |
| SCHEMBL1301778 | 0.89 | TDP1 (0.49) | SIRT5TDP1RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269162-A1 | UBIQUITIN PROTEASOME SYSTEM PROFILING FOR DIAGNOSIS OF CHRONIC LIVER DISEASE | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-11-03 | — | — | US | disclosed |
| WO-2011069009-A1 | POLYUBIQUITIN LEVELS AS A PROGNOSTIC INDICATOR IN LEUKEMIA | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011028488-A1 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR PROLIFERATIVE HEMATOLOGICAL DISORDERS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028489-A1 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053198-A1 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR PROLIFERATIVE HEMATOLOGICAL DISORDERS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-03-03 | — | — | US | disclosed |
| US-20110053197-A1 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-03-03 | — | — | US | disclosed |
| US-20110053199-A1 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-03-03 | — | — | US | disclosed |
| US-20080118940-A1 | PROTEASOMAL PEPTIDASE ACTIVITY AND THE USE THEREOF IN CLINICAL APPLICATIONS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2008-05-22 | — | — | US | disclosed |
| EP-1123412-B1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6613541-B1 | Pharmacology; bioassay; proteolysis; enzyme inhibitors; use to provide guidance for selecting dose amount and dose frequency of proteasome inhibitors for treatment of cancer, inflammatory and autoimmune diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20010051654-A1 | Treatment of inflammatory and autoimmune diseases | ELLIOTT PETER J (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1123412-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023614-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051654-A1 | Treatment of inflammatory and autoimmune diseases | NFKBIA, IKBKG, PSMB1 | SIRT5 2419/4885TDP1 3353/4885RAB9A 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.